Study protocol of the DUtch PARkinson Cohort (DUPARC): a prospective, observational study of de novo Parkinson’s disease patients for the identification and validation of biomarkers for Parkinson’s disease subtypes, progression and pathophysiology

Autor:	Boertien, Jeffrey M., van der Zee, Sygrid, Chrysou, Asterios, Gerritsen, Marleen J. J., Jansonius, Nomdo M., Spikman, Jacoba M., van Laar, Teus, Verwey, N. A., van Harten, B., Portman, A. T., Langedijk, M. J. H., Oomes, P. G., Jansen, B. J. A. M., van Wieren, T., van den Bogaard, S. J. A., van Steenbergen, W., Duyff, R., van Amerongen, J. P., Fransen, P. S. S., Polman, S. K. L., Zwartbol, R. T., van Kesteren, M. E., Braakhekke, J. P., Trip, J., Koops, L., de Langen, C. J., de Jong, G., Hartono, J. E. S., Ybema, H., Bartels, A. L., Reesink, F. E., Postma, A. G., Vonk, G. J. H., Oen, J. M. T. H., Brinkman, M. J., Mondria, T., Holscher, R. S., van der Meulen, A. A. E., Rutgers, A. W. F., Boekestein, W. A., Teune, L. K., Orsel, P. J. L., Hoogendijk, J. E., van Laar, T.
Přispěvatelé:	Graduate School, Amsterdam Gastroenterology Endocrinology Metabolism, Perceptual and Cognitive Neuroscience (PCN), Clinical Neuropsychology, Movement Disorder (MD)
Jazyk:	angličtina
Předmět:	Male Oncology medicine.medical_specialty Parkinson's disease Neurology Disease Validation Studies as Topic lcsh:RC346-429 Cohort Studies Study Protocol 03 medical and health sciences 0302 clinical medicine Cognition Neuropsychology Internal medicine Observational study Humans Medicine Neurochemistry Prospective Studies 10. No inequality Prospective cohort study Gastrointestinal microbiome lcsh:Neurology. Diseases of the nervous system Aged Netherlands Retrospective Studies 030304 developmental biology 0303 health sciences business.industry Longitudinal studies Microbiota Neurodegenerative diseases General Medicine Middle Aged medicine.disease 3. Good health Parkinson disease Observational Studies as Topic Ophthalmology Cohort Disease Progression Female Neurology (clinical) business Gastrointestinal function 030217 neurology & neurosurgery Biomarkers
Zdroj:	BMC neurology, 20(1):245. BioMed Central BMC Neurology, Vol 20, Iss 1, Pp 1-11 (2020) BMC Neurology BMC NEUROLOGY, 20(1):245. BioMed Central Ltd.
ISSN:	1471-2377
DOI:	10.1186/s12883-020-01811-3
Popis:	Background Parkinson’s Disease (PD) is a heterogeneous, progressive neurodegenerative disorder which is characterized by a variety of motor and non-motor symptoms. To date, no disease modifying treatment for PD exists. Here, the study protocol of the Dutch Parkinson Cohort (DUPARC) is described. DUPARC is a longitudinal cohort study aimed at deeply phenotyping de novo PD patients who are treatment-naïve at baseline, to discover and validate biomarkers for PD progression, subtypes and pathophysiology. Methods/design DUPARC is a prospective cohort study in which 150 de novo PD subjects will be recruited through a collaborative network of PD treating neurologists in the northern part of the Netherlands (Parkinson Platform Northern Netherlands, PPNN). Participants will receive follow-up assessments after 1 year and 3 years, with the intention of an extended follow-up with 3 year intervals. Subjects are extensively characterized to primarily assess objectives within three major domains of PD: cognition, gastrointestinal function and vision. This includes brain magnetic resonance imaging (MRI); brain cholinergic PET-imaging with fluoroethoxybenzovesamicol (FEOBV-PET); brain dopaminergic PET-imaging with fluorodopa (FDOPA-PET); detailed neuropsychological assessments, covering all cognitive domains; gut microbiome composition; intestinal wall permeability; optical coherence tomography (OCT); genotyping; motor and non-motor symptoms; overall clinical status and lifestyle factors, including a dietary assessment; storage of blood and feces for additional analyses of inflammation and metabolic parameters. Since the start of the inclusion, at the end of 2017, over 100 PD subjects with a confirmed dopaminergic deficit on FDOPA-PET have been included. Discussion DUPARC is the first study to combine data within, but not limited to, the non-motor domains of cognition, gastrointestinal function and vision in PD subjects over time. As a de novo PD cohort, with treatment naïve subjects at baseline, DUPARC provides a unique opportunity for biomarker discovery and validation without the possible confounding influences of dopaminergic medication. Trial registration NCT04180865; registered retrospectively, November 28th 2019.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::792e0d2a63c6874cd0f04d3cc1a57af0 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.